Could anktiva help long COVID sufferers? new trial launches
NCT ID NCT07123727
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 39 times
Summary
This study tests a drug called Anktiva (NAI) in 40 adults with Long COVID—symptoms that stick around after a COVID infection clears. The main goal is to see if the drug is safe, and researchers will also check if it helps reduce symptoms. Participants must be between 18 and 70 and have had a confirmed COVID infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chan Soon-Schiong Institute for Medicine (CSSIFM)
RECRUITINGEl Segundo, California, 90245, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.